NewsRoom

Archives: Search / 2019 / 2018 / 2017 / 2016 / 2015 / 2014

201320122011201020092008

Dec 19, 2019
MEI Pharma Announces Closing of Public Offering of Common Stock
Dec 17, 2019
MEI Pharma Announces Pricing of Public Offering of Common Stock
Dec 16, 2019
MEI Pharma Announces Proposed Public Offering of Common Stock
Nov 12, 2019
MEI Pharma to Present at the Stifel 2019 Healthcare Conference
Nov 7, 2019
MEI Pharma Reports First Quarter Fiscal Year 2020 Results and Operational Highlights
--ME-401 emerging as potential best-in-class PI3K delta inhibitor, with Phase 2 study intended to support accelerated approval with FDA in follicular lymphoma underway--
Oct 3, 2019
MEI Pharma Announces Updated Clinical Data from ME-401 Phase 1b Study in Patients with Indolent B-cell Malignancies
--MEI Investor and Analyst Event Webcast Tomorrow, October 4, 2019, at 8:00 a.m. Eastern Time--
Sep 23, 2019
MEI Pharma to Host Investor and Analyst Event on October 4, 2019
Aug 29, 2019
MEI Pharma to Present at the 2019 Wells Fargo Healthcare Conference
Aug 28, 2019
MEI Pharma Reports Fiscal Year 2019 Results and Operational Highlights
- Clinical Progress Continues Across Oncology Portfolio, Highlighted by Expanding ME-401 Data Set Supporting Expedited Development Strategies and Additional Combination Therapy Opportunities -
Aug 21, 2019
MEI Pharma to Release 2019 Fiscal Year End Financial Results and Provide Corporate Update on August 28, 2019
Jul 3, 2019
MEI Pharma Appoints Longtime Industry Consultant and Executive Tamar Howson to its Board of Directors
Jun 21, 2019
MEI Pharma Presents Updated Clinical Data from the ME-401 Phase 1b study in Patients with Indolent B-cell Malignancies at the 2019 International Conference on Malignant Lymphoma (ICML)
Jun 3, 2019
MEI Pharma Presents Updated Clinical Data from the ME-401 Monotherapy and in Combination with Rituximab Phase 1b study in Patients with Follicular Lymphoma at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting
Jun 1, 2019
MEI Pharma Presents Clinical Results for ME-344 in Combination with Bevacizumab in Early HER2 Negative Breast Cancer Patients at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting
- Statistically significant biologic anti-tumor activity demonstrated as measured by a reduction in Ki67 in patients treated with ME-344 compared to an increase in patients receiving placebo -
May 31, 2019
MEI Pharma to Present at the Jefferies 2019 Global Healthcare Conference